What Does Negative for High-Grade Urothelial Carcinoma Mean?

A urine cytology report that reads “Negative for High-Grade Urothelial Carcinoma” (often abbreviated NHGUC) means that a pathologist examined cells in your urine sample and did not find signs of an aggressive bladder or urinary tract cancer. This is the most common and most reassuring result category in the standardized system pathologists use to report urine cytology, but it comes with important nuance. The result is specifically about high-grade cancer, and it does not rule out every type of urinary tract problem, including certain lower-grade tumors that urine cytology is not very good at catching.

What Urine Cytology Actually Tests For

When your doctor orders a urine cytology test, the goal is to look for abnormal cells shed from the lining of your urinary tract. You either provide a regular voided urine sample or have urine collected during a procedure. A pathologist then examines the cells under a microscope, looking for features associated with cancer: irregular nuclear shapes, unusual size ratios between the nucleus and the rest of the cell, and dark-staining nuclei.

The reporting system most labs now use is called The Paris System for Reporting Urinary Cytology. Under this framework, results fall into several categories, ranging from “Negative for High-Grade Urothelial Carcinoma” at the reassuring end to “Positive for High-Grade Urothelial Carcinoma” at the concerning end, with intermediate categories like “Atypical Urothelial Cells” and “Suspicious for High-Grade Urothelial Carcinoma” in between. The system was specifically designed to focus on high-grade urothelial carcinoma because that is the type of bladder cancer most likely to progress, invade deeper tissue, and threaten a person’s life.

When your report says NHGUC, the pathologist is telling your doctor: “I looked at these cells carefully, and I do not see the hallmarks of high-grade cancer.” That is good news, but it is a targeted statement. The test is optimized to catch the most dangerous form of the disease, not every abnormality that could exist in the urinary tract.

Why “Negative” Does Not Mean “Completely Cancer-Free”

This is where a lot of understandable confusion happens. A negative cytology result does not guarantee that no cancer exists anywhere in the urinary tract. The main reason is that urine cytology has a well-known blind spot for low-grade urothelial tumors. Low-grade cancers shed cells that look much more similar to normal urothelial cells, so a pathologist examining the sample may not be able to distinguish them from healthy tissue. Multiple studies and reviews confirm that cytology has low sensitivity for low-grade disease.¹ One analysis found that sensitivity dropped to roughly 10% for low-grade tumors, compared to about 51% for high-grade tumors.²

In practical terms, this means urine cytology catches about half of high-grade cancers when they are present, and it misses the vast majority of low-grade ones. If you have a low-grade papillary tumor growing in your bladder, your urine cytology could very easily come back negative. This is not a failure of the pathologist reading your slide; it is a fundamental limitation of what the test can detect.

The good news is that low-grade urothelial tumors tend to behave very differently from their high-grade counterparts. They are typically slow-growing, superficial, and much less likely to invade the bladder wall or spread to other organs. They are the type of cancer that often gets managed with periodic surveillance rather than aggressive treatment. So while a negative cytology result does not exclude them, missing a low-grade tumor on a single urine test is generally less clinically dangerous than missing a high-grade one.

Things That Can Complicate the Reading

Even when cancer is not present, a urine sample can contain cells that look suspicious under the microscope. One of the most common challenges pathologists face is telling high-grade cancer cells apart from benign look-alikes. Samples affected by prolonged exposure to urine, inflammation, or prior medical procedures can contain cells that mimic cancer.³

Kidney stones, for example, can irritate the urinary tract lining and cause normal urothelial cells to clump together into sheets or clusters. These cells may show mild darkening of their nuclei and other subtle changes that could, at first glance, raise concern.⁴ Radiation therapy to the pelvic area is another well-known source of confusion. In one prospective study, the majority of urine samples from patients undergoing pelvic radiation showed cellular changes consistent with radiation effects, even though all samples were negative for actual malignant cells.⁵

Urinary tract infections, recent catheterization, and certain medications can also alter how urothelial cells appear. If your pathologist categorized your sample as NHGUC despite the presence of reactive-looking cells, they judged that those changes were benign rather than cancerous. But if your clinical situation is complex, your urologist may still want additional testing.

How Pathologists Reach the Same Conclusion (Or Don’t)

One concern that comes up in cytology is whether different pathologists looking at the same slide would agree on the diagnosis. The answer is: usually yes, but not always. One study examining reproducibility found that about 12% of comparisons between pathologist pairs differed by two or more reporting categories for NHGUC specimens.⁶ That means in a meaningful minority of cases, one pathologist might call something negative while another might call it atypical or even suspicious.

Other research has been more encouraging. A prospective assessment of the Paris System found excellent agreement across all categories, with near-perfect concordance once results were collapsed into a simple negative-versus-positive classification.⁷ The variability tends to concentrate in the gray-zone categories, where cells look slightly abnormal but not clearly malignant. A straightforward NHGUC result, where the cells look clearly benign, is one that pathologists are more likely to agree on.

Urine cytology has long been acknowledged as a challenging test because of this variability and because of its inherent sensitivity limitations.⁸ The Paris System was specifically developed to standardize how pathologists report findings and reduce disagreements. It has helped, but it has not eliminated the issue entirely.

What Your Doctor Typically Does Next

A negative cytology result is rarely the only piece of the puzzle. Urine cytology is generally used alongside other tests, not as a standalone diagnostic tool. The standard approach for evaluating suspected bladder cancer pairs urine cytology with cystoscopy, a procedure where a thin camera is inserted through the urethra to visually inspect the bladder lining.¹ Cytology can serve as a useful additional tool alongside cystoscopy and biopsy.⁹

When the two tests are combined, the diagnostic picture becomes much stronger. One study found that combining cytology and cystoscopy achieved 100% sensitivity and 91% specificity for detecting recurrent superficial urothelial carcinoma.¹⁰ In other words, each test fills in gaps that the other one misses. Cystoscopy can directly visualize tumors that shed normal-looking cells, and cytology can sometimes catch flat, high-grade lesions (like carcinoma in situ) that are hard to see through a camera.

If your doctor ordered urine cytology as part of an initial evaluation for symptoms like blood in the urine, a negative result is reassuring but will almost certainly be followed by cystoscopy if it has not already been done. If there is clinical suspicion and the cytology is negative, the investigation does not stop there.

The Result During Surveillance for Known Bladder Cancer

Many people who see NHGUC on a report are not being evaluated for the first time. They are patients who have already been treated for bladder cancer and are undergoing routine follow-up. Bladder cancer has one of the highest recurrence rates of any cancer, so patients often undergo years of repeated cystoscopies and urine cytology tests to watch for tumors coming back.

In this surveillance setting, a negative cytology result carries a particular meaning: it provides reassurance that high-grade disease has not returned. But the practical impact of that result depends heavily on the patient’s risk level. A study following over 200 patients with non-muscle-invasive bladder cancer found that among patients with low-risk disease, there were no positive urine cytologies at all during the entire surveillance period. Among all risk groups, cytology only changed clinical decision-making in about 0.4% of all tests obtained.¹¹

This finding has practical implications. For patients with low-risk, low-grade bladder cancer history, routine urine cytology adds very little to what cystoscopy alone tells the doctor. Some guidelines are beginning to reflect this by recommending cytology primarily for patients with high-risk disease or those being monitored for carcinoma in situ, where the test performs meaningfully better. If you are in a low-risk surveillance group and wondering why your doctor keeps ordering cytology, it is worth having that conversation.

Upper Urinary Tract Cancers

Urothelial carcinoma does not only occur in the bladder. The same type of cancer can develop in the ureters or the renal pelvis (the part of the kidney that collects urine). These are called upper tract urothelial carcinomas, and they are less common but can be just as serious.

Urine cytology can be used to evaluate for upper tract disease, but its performance there is somewhat different. One study found that urine cytology detected surgically confirmed high-grade upper tract urothelial carcinoma with a sensitivity of about 65%.¹² Another study using a template-based approach found that when positive and suspicious-for-cancer categories were combined, sensitivity for high-grade upper tract disease reached about 71%, with specificity over 90%. For low-grade upper tract disease, sensitivity dropped to about 21%.¹³

If your NHGUC result came from a sample collected specifically to evaluate the upper urinary tract, the same caveats apply as for the bladder: the test is better at catching high-grade disease than low-grade, and it works best when combined with imaging or direct visualization through a ureteroscope. A negative result is encouraging, but it does not definitively exclude upper tract cancer, especially low-grade tumors.

Emerging Urine Biomarkers

Because traditional urine cytology has clear limitations, particularly for low-grade disease and for reducing the need for invasive cystoscopy, researchers have been working on molecular urine tests that could do better. Several of these are already available or in advanced stages of evaluation.

A recent review of urinary biomarkers found that most molecular tests demonstrated higher sensitivity than standard cytology, especially for detecting high-grade recurrence. Several of these tests reported negative predictive values above 95%, meaning that when the test says there is no cancer, it is right more than 95% of the time.¹⁴ Tests with strong evidence in the surveillance setting include those that detect specific genetic mutations, DNA methylation patterns, or protein markers shed by tumor cells.

That said, the current evidence supports using these biomarkers as add-ons to cystoscopy, not replacements for it. No urine test, whether traditional cytology or a newer molecular assay, has yet proven reliable enough on its own to tell patients they can safely skip cystoscopy. The hope is that a highly reliable negative result from one of these tests could eventually allow some patients to space out their cystoscopies, reducing the burden of repeated invasive procedures. For now, though, that remains an area of active research rather than standard practice.

Artificial Intelligence in Urine Cytology

Another area of development that could affect how future NHGUC results are generated involves artificial intelligence. AI systems are being trained to analyze digitized images of urine cytology slides, identifying and classifying cells in a way that aligns with the Paris System categories. One validated AI system was able to predict high-grade urothelial carcinoma from digitized cytology slides with higher sensitivity than pathologists, while maintaining comparable accuracy overall.¹⁵

Another AI pipeline achieved roughly 83% agreement with both expert cytology interpretation and with the gold standard of tissue biopsy results.¹⁶ A separate deep-learning tool specifically designed for post-surgical follow-up was built to distinguish between high-risk suspicious cells and lower-risk atypical cells on digitized slides.¹⁷

These tools are not replacing pathologists, but they could help improve consistency and catch cases that a human eye might miss on a busy day. Given that interobserver variability remains a real issue in cytology, AI-assisted screening could eventually make NHGUC results more reliable. For now, most of these systems are in validation phases or early clinical use at specialized centers rather than standard deployment across all labs.

The Cost Question

For patients undergoing long-term surveillance, the economics of repeated testing matter. Bladder cancer is one of the most expensive cancers to manage on a per-patient basis, largely because of the years of follow-up testing required. A systematic review of cost-effectiveness found that the least expensive surveillance strategy over 20 years involved cytology followed by white-light cystoscopy. However, no single strategy was clearly cost-effective more than half the time, and strategies that added newer biomarkers or enhanced cystoscopy techniques improved detection rates but at substantially higher cost per life-year gained.¹⁸

What this means practically is that urine cytology persists in surveillance protocols partly because it is inexpensive and noninvasive compared to alternatives. Even with its sensitivity limitations, it remains a reasonable screening layer, especially for patients at higher risk of high-grade recurrence. The economic calculus could shift as newer molecular tests become cheaper and more widely available, but that transition has been slow.

What to Ask Your Doctor

If you have received an NHGUC result, there are a few questions worth raising at your next appointment. First, ask whether cystoscopy has been performed or is planned. Cytology alone is not sufficient to rule out bladder cancer, and the two tests work best together. Second, if you are in surveillance for a previously treated bladder cancer, ask about your risk category. Patients with low-grade, low-risk disease may not benefit much from routine cytology, and your doctor may be open to adjusting the surveillance schedule. Third, if your sample showed any reactive or atypical-looking cells that were ultimately classified as benign, ask what might have caused those changes and whether any follow-up is warranted.

Finally, keep in mind that a single NHGUC result is a snapshot, not a guarantee. Urine cytology is most useful as part of a pattern of results over time. A series of negative results is more reassuring than any single one, particularly for patients being monitored after treatment. The limitations of cytology are real, but so is its value when used appropriately and interpreted in context alongside your full clinical picture.